FDA Panel Votes Against Amgen's Xgeva For Prostate Cancer
A U.S. Food and Drug Administration advisory committee on Wednesday recommended against approving Amgen Inc.'s bone cancer drug Xgeva for patients with prostate cancer that has not spread to the bones....To view the full article, register now.
Already a subscriber? Click here to view full article